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Abstract 
This study was undertaken to investigate the pregnancy outcomes in patients with systemic 
lupus erythematosus (SLE) and the appropriate timing of pregnancy. We performed a ret-
rospective evaluation of 183 pregnancies with SLE at Catholic University Medical Center 
during the 13-year period from 1998 to 2010. Pregnancy outcomes were compared according 
to SLE characteristics. The predictive value of the different cut-off points of the stable period 
before conception on adverse pregnancy outcomes was calculated by ROC (Receiver op-
erating characteristics) curve analysis. In multivariate analysis, the presence of antiphospho-
lipid antibodies (aPLs) increased the risk of pregnancy loss (p<0.0001) and premature birth 
(p=0.0040). Active disease at conception increased the risk of premature birth (p< 0.0001) 
and complications (IUGR, PIH, or both) (p= 0.0078). The other predictor of complications 
was found to be lupus flare (p=0.0252). At a cut-off level of stable period of 4 months before 
conception, sensitivity and specificity were 70.8% and 53.2%, 71.4% and 61.5%, and 63.6 % and 
59.8 %, respectively on reducing pregnancy loss, premature birth, and complications. Preg-
nancies with aPLs, active disease at conception and SLE flares are at a higher risk of adverse 
outcomes. It is essential that disease activity remains stable at least 4 months before con-
ception, for favorable pregnancy outcomes. 
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Introduction 
Systemic lupus erythematosus (SLE) is a multi-
system  autoimmune  connective  tissue  disorder  that 
primarily  affects  women  of  childbearing  age.  It  is 
recognized that the pregnancy may exacerbate SLE, 
and the SLE may increase the pregnancy complica-
tions,  including  spontaneous  abortion,  premature 
delivery, intrauterine growth restriction (IUGR), and 
preeclampsia [1].  
However, the other studies found no difference 
in flares between pregnant and non-pregnant patients 
with SLE [2,3]. The rates of SLE flares in pregnancies 
have been reported to range from 13–68 %, but rates 
have been reported to be reduced if pregnancy is de-
layed until disease is quiescent [2-7]. 
The timing of conception, management of preg-
nancy and treatments in women affected by SLE, as 
well  as  SLE  inheritance,  are  challenging  issues  for 
obstetricians worldwide, in particular in Asian coun-
tries  where  there  is  lack  of  reports  on  these  issues 
concerning  Asian  pregnant  women.  Therefore,  it  is 
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mandatory to investigate the timing of pregnancy in 
women with complicating SLE, as well as the perina-
tal management, which is important for the reduction 
of the mortality of women and infants, and the im-
provement  of  neonatal  survival  rate  in  pregnancy 
complicating SLE. Even though several recommenda-
tions  for  the  management  of  SLE  have  been  devel-
oped  and  pregnancy  recommended  to  be  planned 
when SLE is in remission, there is lack of evidence 
regarding  how  many  months  the  remission  period 
should last before experiencing the trial of pregnancy 
in  order  to  decrease  adverse  pregnancy  outcomes 
[8-10].  
This study was undertaken to investigate preg-
nancy outcomes in Asian women with complicating 
SLE, as well as the appropriate timing of pregnancy, 
according  to  disease  activity  to  improve  the  preg-
nancy outcomes. 
Materials and methods 
We  performed  a  retrospective  study  of  183 
pregnancies  occurring  in  143  patients  with  SLE  (as 
defined  by  the  1997  revised  American  College  of 
Rheumatology  [ACR]  criteria)  [11]  managed  in  the 
department of internal medicine and  department of 
obstetrics  and  gynecology  at  Catholic  University 
Medical  Center,  Korea,  during  a  period  between  1 
January  1998  and  31  December  2010.  Fifteen  preg-
nancies with SLE were excluded because we did not 
know pregnancy outcomes due to follow up loss. 
Demographic  data,  SLE  clinical  manifestations 
and treatment, SLE disease activity index (SLEDAI) 
[12], maternal SLE status (flare or no flare), pregnancy 
data,  its  outcome  and  therapy  were  recorded  from 
medical  charts.  Laboratory  data  included  complete 
blood  count,  urinalysis,  antinuclear  antibodies 
(ANA),  anti-Ro/SSA  antibodies,  anti-La/SSB  anti-
bodies, and antiphospholipid antibodies (aPLs). Posi-
tive aPLs were defined as more than one presence of 
anti-cardiolipin  Antibodies,  β2  glycoprotein,  or  lu-
pus anticoagulant antibody. The pregnancy outcomes 
retrieved were live births including term and preterm 
births,  pregnancy  loss  including  miscarriages,  still-
births and neonatal deaths, as well as gestational age 
at birth in weeks, infant birth weight, delivery mode, 
lupus  flare,  oligohydramnios,  preterm  premature 
rupture of membrane, IUGR, and pregnancy induced 
hypertention (PIH), low Apgar score, and congenital 
anomaly. A flare was defined as onset of new signs of 
SLE  disease  activity  during  pregnancies  in  patients 
previously  in  remission.  The  criteria  for  relapse  or 
ﬂare-up of SLE included new evidence of acute syno-
vitis, serositis, pruritis, typical skin lesions, new psy-
chological or neurological symptoms (in the absence 
of  eclampsia),  haematological  parameter  revealing 
leucopenia, thrombocytopenia or active renal disease 
during pregnancy. Renal involvement was deﬁned as 
the  following:  proteinuria  [500  mg/day  (in  the  ab-
sence  of  preeclampsia),  cellular  casts  in  urine  and 
dysmorphic hematuria] [13]. SLE flare including renal 
or CNS involvement and requiring hospitalization for 
management of flare up was classified as severe type. 
Premature birth was defined as a live birth occurring 
before 37 weeks of gestation, stillbirths as no signs of 
life in a fetus delivered after 24 weeks of gestation, 
and low birth weight as <2.5 kg birth weight of infant 
at term. Pregnancy outcomes were compared between 
SLE patients with and without different characteris-
tics  including  lupus  nephritis,  ANA,  anti-Ro/SSA 
antibodies, anti-La/SSB antibodies, aPLs, disease ac-
tivity at pregnancy and lupus flares during pregnan-
cy. 
Statistical analysis 
Statistical  analysis  was  performed  by  t-test, 
chi-square test, or Fisher’s exact test as appropriate. 
Stepwise  multiple  logistic  regression  analysis  was 
employed  to  find  the  risk  factors  for  adverse  preg-
nancy outcomes. The predictive value of the different 
cut-off points of the stable time period of SLE before 
conception on adverse pregnancy outcomes including 
pregnancy loss, premature birth, and complications of 
IUGR, PIH, or both was calculated by ROC (Receiver 
operating  characteristics)  curve  analysis.  Statistical 
calculations were performed with SPSS version 19.0 
(SPSS, Chicago, IL, USA). A p-value <0.05 was con-
sidered significant. 
Results 
Patient characteristics of pregnant women 
Mean age at the time of conception was 30.4±3.2 
years, and mean SLE duration was 69.8±47.8 months. 
Mean numbers of pregnancies and deliveries per pa-
tient  were  1.1±1.3  and  0.35±0.5,  respectively.  Mean 
gestational age at delivery was 37.2±3.5 weeks.  Of 
the 183 women who conceived, the disease status of 
SLE was active in 56 (30.6%) and stable in 127 (69.4%) 
patients. 37 (20.3%) had a history of lupus nephritis 
and 47 (25.8%) were positive of aPLs. 
ANA was positive in 124 of 178 tested (69.7 %), 
anti-Ro in 50 of 134 tested (37.3%), anti-La in 15 of 115 
tested  (13.0%).  Of  the  183  women,  137  (76.5%)  re-
ceived treatment for SLE during pregnancy including 
glucocorticoid,  hydroxychloroquine,  aspirin,  intra-
venous gamma globulin, heparin, or plasmapheresis 
(Table 1).  




Table 1. Baseline Characteristics 
Age at conception (years)  30.0 ± 3.2 (22-39) 
Previous pregnancies  1.1 ± 1.3 (0-7) 
Previous deliveries  0.35 ± 0.51 (0-2) 
Gestational age at delivery (weeks)  37.2 ± 3.5 (16.0-41.6) 
Disease duration before conception(months)  69.8±47.8 (0-240) 
SLE status at conception   
Active  56 (30.6) 
Stable  127 (69.4) 
Lupus Nephritis   37 (20.3) 
aPLs, positive  47 (25.8) 
Autoantibody profile, positive   
Antinuclear antibody  124 (69.7) 
Anti-SSA(Ro) antibody  50 (37.3) 
Anti-SSB(La) antibody  15 (13.0) 
Medication during pregnancy  137 (76.5) 
Glucocorticoid (less than 15 mg per day)  128 (73.1) 
Glucocorticoid pulse therapy  16 (9.1) 
Hydroxychloroquine  8 (4.6) 
Low dose aspirin  39 (22.4) 
IVGV  10 (5.7) 
Heparin  8 (4.6) 
Plasmapheresis  6 (3.4) 
Values are presented as mean±SD (min.-max.) or n(%) 










Pregnancy outcomes in different SLE charac-
teristics including lupus flares  
There was no significant difference in pregnancy 
loss (miscarriage, still birth, neonatal death), prema-
ture  birth,  IUGR  with  and  without  PIH  in  patients 
with  and  without  lupus  nephritis.  The  presence  of 
ANA  was  related  with  pregnancy  loss  (p=0.0154). 
Pregnancy loss and premature birth were significantly 
increased in patients with aPLs (p<0.0001). Pregnancy 
loss, premature birth, and IUGR with PIH were sig-
nificantly increased in patients with active status of 
SLE at conception (p< 0.0001, each). Lupus flare was 
related  with  premature  birth  and  IUGR  with  PIH 




Table 2. Comparison of pregnancy outcomes according to different SLE characteristics 
  No. of 
pregnancies 
Pregnancy Outcomes  delivery  Complications 




p  N  Preterm  Term  p  N*  IUGR  PIH+IUGR  p 
Nephritis           0.4748        0.0594        0.1473 
Yes  37(20.4)  4(10.8)  2(5.4)  2(5.4)  29(78.4)    33  14(42.4)  19(57.6)    35  4(11.4)  7(20.0)   
No  144(79.6)  13(9.0)  3(2.1)  5(3.5)  123(85.4)    132 34(25.8)  98(74.2)    117 20(17.1)  10(8.6)   
ANA            0.0154        0.8180        0.9992 
Yes  124(70.1)  16(12.9)  4(3.2)  5(4.0)  99(79.8)    109 31(28.4)  78(71.6)    105 17(16.3)  12(11.6)   
No  53(29.9)  0(0.0)  1(1.9)  2(3.8)  50(94.3)    53  16(30.2)  37(69.8)    43  7(15.9)  5(11.4)   
aPLs            <0.0001       <0.0001        0.2225 
Yes  47(26.0)  15(31.9)  4(8.5)  5(10.6)  23(48.9)    33  19(57.6)  14(42.4)    33  3(9.1)  6(18.2)   
No  134(74.0)  2(1.5)  1(0.8)  2(1.5)  129(96.3)    132 29(22.0)  103(78.0)    119 21(17.7)  11(9.2)   
Activity            <0.0001       <0.0001        <0.0001 
Yes  56(30.8)  7(12.5)  6(10.7)  6(10.7)  37(66.1)    49  27(55.1)  22(44.9)    47  6(12.8)  14(29.8)   
No  126(69.2)  10(7.9)  0(0.0)  1(0.8)  115(91.3)    117 22(18.8)  95(81.2)    106 18(17.0)  3(2.8)   
Lupus 
flare 
          0.2278        0.0142        <0.0001 
Yes  92(50.6)  8(8.7)  4(4.3)  6(6.5)  74(80.4)    84  32(38.1)  52(61.9)    83  11(13.3)  17(20.5)   
No  90(49.5)  9(10.0)  2(2.2)  1(1.1)  78(86.7)    82  17(20.7)  65(79.3)    70  13(18.6)  0(0.0)   
By chi-square test or Fisher's exact test 
ANA: antinuclear antibody; aPLs: antiphospholipid antibodies 
* N, not equal to the sum of IUGR and PIH+IUGR due to the omission of other complications 





Pregnancy outcomes in patients with disease 
status of SLE at conception 
There  were  115  live  births  (91.3%),  10  miscar-
riages (7.9%), no stillbirth and 1 neonatal death (0.8%) 
in a group with stable status of SLE at conception and 
37 live births (66.1%), 7 miscarriages (12.5%), 6 still-
births  (10.7%)  and  6  neonatal  death  (10.7%)  in  the 
other group with active status of SLE at conception. 
There were significant differences in gestational age at 
delivery (p=0.0003), neonatal birth weight (p<0.0001), 
low  birth  weight  less  than  2.5  kg  (p<0.0001),  the 
presence of lupus flare during pregnancy (p<0.0001), 
severe type of lupus flare (p<0.0001), pregnancy loss 
(p<0.0001), PIH (p=0.0422), IUGR with PIH(p<0.0001), 
premature birth (p<0.0001), and low Apgar score (less 
than 7) at 1 min (p<0.0001) and 5 min (p=0.0002), be-
tween two groups (Table 3). 
Analysis of predictors of adverse pregnancy 
outcome by stepwise multiple logistic regres-
sion analysis 
Factors that were analyzed to identify the pre-
dictors  of  adverse  pregnancy  outcome  (pregnancy 
loss, preterm births, IUGR) included antinuclear an-
tibody, aPLs, disease activity at conception, and lupus 
flare.  Among  these,  aPLs  (OR  21.35;  95%  CI 
6.50–70.17; p<0.0001) was found to be the predictors 
of pregnancy loss in patients with SLE. The remaining 
factors  were  not  associated  with  pregnancy  loss 
(p>0.05).  The  predictors  of  preterm  delivery  in  our 
SLE patients were active status of SLE at conception 
(OR 5.52; 95% CI 2.38–12.83; p< 0.0001) and aPLs (OR 
3.64;  95%  CI 1.51–8.79;  p=0.0040).  The  predictors  of 
complications of IUGR, PIH, or both were found to be 
active status of SLE at conception (OR 3.23; 95% CI 
1.36-7.67; p= 0.0078) and lupus flare during pregnancy 
(OR 2.44; 1.12-5.34; p=0.0252) (Table 4). 
Table 3. Pregnancy outcomes in SLE patients with disease status of SLE at conception 
  Activity at conception  p-value 
Stable state  Active state 
Gestational age at delivery  38.1±1.8  35.0±5.3  0.0003 
Birth weight  2.85±0.50  2.15±0.82  <0.0001 
Low birth weight (<2.5 kg)  28 (24.1)  26 (57.8)  <0.0001 
Delivery mode       
Vaginal delivery  61 (52.1)  23 (47.9)  0.6224 
Cesarean delivery  56 (47.9)   25 (52.1)   
Lupus flare  Yes  Mild  38 (80.9)   20 (42.6)  <.0001 
Severe  8 (17.0)  26 (55.3)   
No    81 (63.8)  10 (17.6)   
Pregnancy loss   11 (8.7)  19 (33.9)  <.0001 
Oligohydramnios  4 (3.8)  1 (2.1)  1.0000 
PPROM  5 (4.7)  0 (0.0)  0.3253 
PIH  13 (12.3)  12 (25.5)  0.0422 
IUGR  18 (17.0)  6 (12.8)  0.5230 
PIH+IUGR  3 (2.8)  14 (29.8)  <.0001 
Preterm birth  22 (18.8)  27 (55.1)  <0.0001 
Low apgar score (< 7 at 1 min)  10 (8.6)  17 (37.0)  <0.0001 
Low apgar score (< 7 at 5 min)  4 (3.5)  11 (23.9)  0.0002 
Congenital anomaly  3 (4.8)  3 (10.3)  0.3750 
By t-test, chi-square test, or Fisher’s exact test 
Pregnancy loss includes miscarriage, still birth, and neonatal death; PPROM: Preterm premature rupture of membrane; PIH: Pregnancy 
induced hypertension; IUGR: Intrauterine growth restriction 
Table 4. Relation of pregnancy outcomes with different SLE features and SLE flares 
  Pregnancy loss  Preterm  Complications 
Factors  OR  95% CI  p  OR  95% CI  p  OR  95% CI  p 
ANA  4.81  0.97-23.79  0.0544  0.51  0.22-1.20  0.1244       
aPLs  21.35  6.50-70.17  <0.0001  3.64  1.51-8.79  0.0040       
Activity        5.52  2.38-12.83  <0.0001  3.23  1.36-7.67  0.0078 
Lupus-flare              2.44  1.12-5.34  0.0252 
We presented only the values which are significant at 0.15 level in stepwise multiple logistic regression. 





The cut-off stable time period of SLE before 
conception for adverse pregnancy outcomes 
ROC curve analysis of a stable period of SLE for 
adverse pregnancy outcomes (pregnancy loss, prem-
ature birth, and complications of IUGR, PIH or both) 
are shown in Figure 1a-1c. The area below the graph 
did  reach  statistical  significance  of  pregnancy  loss, 
premature birth and complications of IUGR, PIH, or 
both  (p<  0.001,  each)  and  area  under  the  curves 
(AUCs)  were  0.707  (95%  CI,  0.608-0.805),  0.711(95% 
CI,  0.623-0.799),  and  0.675  (96%CI,  0.589-0.762),  re-
spectively.  At  a  cut-off  level  of  stable  period  of  4 
months before conception, sensitivity was 70.8% and 
specificity 53.2% on reducing pregnancy loss, sensi-
tivity  was  71.4%  and  specificity  61.5%  on  reducing 
premature birth, and sensitivity was 63.6 % and spec-
ificity was 59.8 % on reducing complications of IUGR, 
PIH, or both.  
 
 
   
 
Figure 1. ROC curve for prediction of adverse pregnancy outcomes. (A) ROC curve for prediction of pregnancy loss by the 
stable period of SLE. At a cut-off of 4 month, sensitivity was 70.8% and specificity 53.2% on reducing pregnancy loss. (B) ROC 
curve for prediction of premature birth by the stable period of SLE. At a cut-off of 4 month, sensitivity was 71.4% and 
specificity 61.5% on reducing premature birth. (C) ROC curve for prediction of complications during pregnancy (PIH, IUGR, 
or both) by the stable period of SLE. At a cut-off of 4 month, sensitivity was 63.6 % and specificity was 59.8 % on reducing 
complications of IUGR, PIH, or both. 






Because SLE is a multi-system, complex illness, 
pregnancy is a challenge for lupus patients and their 
physicians.  It  is  recognized  that  pregnancies  in 
women with SLE show high rates of SLE flare, hy-
pertension,  nephritis,  and  preeclampsia,  although 
some reports show different results. Fetal complica-
tions  included  spontaneous  abortion,  stillbirth,  neo-
natal death, and IUGR [14]. These risks are increased 
in the presence of anticardiolipin antibodies or lupus 
anticoagulant, lupus nephritis or hypertension and if 
there is either active disease at the time of conception 
or first presentation of SLE during pregnancy. 
 In our study, the history of lupus nephritis was 
not  related  with  adverse  pregnancy  outcomes  in-
cluding pregnancy loss, premature birth, IUGR, and 
PIH.  Antinuclear  antibody  was  related  with  preg-
nancy loss in univariate analysis, but not in multivar-
iate analysis. Active status of SLE at conception was 
related  with  all  adverse  outcomes  including  preg-
nancy loss, PIH, IUGR with PIH, lupus flare, prema-
ture birth, neonatal low birth weight, low Apgar score 
at 1 and 5 min. 
Several  studies  have  suggested  that  nephritis 
may  contribute  to  adverse  maternal  and  fetal  out-
comes [15,16]. However, studies of the associations of 
SLE  and  lupus  nephritis  with  pregnancy  outcomes 
showed  significant  variation  with  respect  to  study 
design, definitions, statistical methods, bias and out-
comes. Early studies reported poor clinical outcomes, 
but a number of recent papers have shown that out-
comes are better than previously thought. These dif-
ferences  may  reflect  the  changing  clinical  environ-
ment and the emergence of new therapeutic options. 
We  did  not  find  association  of  adverse  pregnancy 
outcomes with lupus nephritis. 
It  has  been  proposed  that  SLE  patients  with 
quiescent  renal  disease  do  not  have  adverse  preg-
nancy  outcomes  [17],  and  our  results  support  this 
finding.  It  seems  that  adverse  pregnancy  outcomes 
associated with active renal disease at conception and 
not quiescent renal disease, even though we need to 
monitor the SLE patients with lupus nephritis, closely. 
In  univariate  and  multivariate  analysis,  lupus 
ﬂare in pregnancy was found to be related to adverse 
pregnancy complications of IUGR, PIH, or both in our 
patients,  consistent  with  previous  reports  [5].  Most 
studies have shown that lupus tends to ﬂare during 
pregnancy  and  after  pregnancy;  in  some  patients 
ﬂares were mild such as arthritis, constitutional and 
cutaneous  manifestations,  and  in  others  they  were 
more serious problems affecting the kidneys and cen-
tral nervous system [5,6,18]. The severe types of lupus 
flare  were  occurred  more  frequently  when  women 
with SLE were at active disease status before concep-
tion in our study.  
Our study demonstrated that aPLs were related 
with pregnancy loss and premature birth in univariate 
and multivariate analysis. The aPLs are the major risk 
factor for pregnancy loss in patients with SLE and in 
those  with  primary  antiphospholid  antibody  syn-
drome. These antibodies play a direct pathogenic role 
not only by aPL-mediated thrombophilia of the pla-
centa, but also by the direct effect of antibodies  on 
trophoblast possibly through exposed anionic phos-
pholipids and/or adherent β2 glycoprotein, resulting 
in  altered  trophoblast  intercellular  fusion,  gonado-
tropin secretion and trophoblast invasiveness [19]. A 
previous study has shown that positive aPLs are pre-
dictive of both premature births and pre-eclampsia, 
but not of pregnancy loss [20]. We can speculate that 
aPLs are stronger risk factors for pregnancy loss than 
disease activity at conception, because disease activity 
did not reach statistical significance on pregnancy loss 
in multivariate analysis. 
Over the last decades, improvement of survival 
rate and quality of life in SLE patients has led to an 
increased number of pregnancies observed during the 
course of the disease. 
However, it has been reported that if SLE is ac-
tive at conception, then the patient has a high risk of 
having a disease flare during pregnancy; if the disease 
is in remission then the risk is reduced [21]. Pregnancy 
should therefore be planned when SLE is in remission 
[9]. So, some rheumatologists say that the risk of flare 
seems to depend on the level of maternal disease ac-
tivity in the 6–12 months before conception [10]. 
However, there is lack of reports about the stable 
or remission period before the trial of pregnancy to 
decrease  adverse  pregnancy  outcome.  Even  though 
fertility  is  generally  conserved  in  SLE  patients,  the 
timing  for  the  trial  of  pregnancy  can  be  challenge, 
because  maternal  age  at marriage  and  first  birth  in 
general  population  is  getting  older  not  only  in 
high-income countries but also middle-income coun-
tries in Asia where social activity of women is getting 
higher  and  social  supporting  system  is  not  enough 
yet. Older women are more likely to experience fertil-
ity problems and require assisted reproductive tech-
nology (ART) to conceive. Impact of assisted fertiliza-
tion on disease activity has to be evaluated also [8]. A 
trial and achievement of pregnancy is associated not 
only disease status but also social, cultural, economi-
cal factors, and so on. So, it is important when the 
women with SLE can start the trial of pregnancy. 
Based on our results, pregnancy loss, premature 




PIH, or both were reduced significantly if pregnancy 
occurs after more than 4 months of stable period in 
women with SLE.  
Our study has several limitations. We evaluated 
observational data, and therefore the treatment strat-
egy was not based on randomized assignment. Also, 
we  could  not  observe  all  immunologic  data  we 
planned from the all patients. However, this is a large 
observational data in the East Asian pregnant women 
with SLE and we found cut-off stable time period of 
disease activity before the trial of pregnancy to de-
crease adverse pregnancy outcomes. 
In women with SLE, the present study showed 
that the stable group according to disease activity at 
conception was superior to the active group in terms 
of  success  rate  of  fetal  survival,  full-term  delivery, 
body weight of neonate, complication of IUGR or PIH, 
and SLE flare of the mother, indicating the important 
role of the physicians in consulting patients with SLE 
for the timing of pregnancy. 
We conclude that in order to achieve favorable 
pregnancy outcomes it is essential that disease activity 
remains stable at least 4 months at the time of con-
ception,  and  that  pregnancy  is  managed  by  experi-
enced rheumatologists and obstetricians. 
Conflict of Interest 
We declare that there are no conﬂicts of interest 
and that the study has met institutional review board 
approval.  The  study  has  not  been  previously  pub-
lished in any form or shape. 
References 
1.   Cunningham FG, Gant NF, Leveno I, et al. Diabetes. In: Cun-
ningham FG, Gant NF, Leveno KJ, et al., eds. Williams obstet-
rics (21st ed). NY: Appleton-Century-Crosfts. 2002: 1385–1389  
2.   Lockshin  MD,  Reinitz  E,  Druzin  ML,  Murrman  M,  Estes  D. 
Lupus  pregnancy:  a  case  control  prospective  study  demon-
strating  absence  of  lupus  exacerbation  during  or  after  preg-
nancy. Am J Med 1984; 77: 893–898. 
3.   Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. 
Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392–
1397. 
4.   Petri  M.  Prospective  study  of  systemic  lupus  erythematosus 
pregnancies. Lupus 2004; 13: 688–689. 
5.   Chakravarty  EF, Colon  I,  Langen  ES,  Nix DA,  El-Sayed  YY, 
Genovese  MC,  et  al.  Factors  that  predict  prematurity  and 
preeclampsia in pregnancies that are complicated by systemic 
lupus  erythematosus.  Am  J  Obstet  Gynecol 2005; 192:  1897–
1904. 
6.   Georgiou  PE,  Politi  EN,  Katsimbri  P,  Sakka  V,  Drosos  AA. 
Outcome of lupus pregnancy: a controlled study. Rheumatol-
ogy 2000; 39: 1014–1019. 
7.   Georgiou PE F, Font J, Cervera R, Muñoz F, Cararach V, Balasch 
J. Obstetrical outcome of pregnancy in patients with systemic 
lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol 
Reprod Biol 1999; 83: 137–142. 
8.   Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, 
Dostal C, et al. EULAR recommendations for the management 
of systemic lupus erythematosus. Report of a Task Force of the 
EULAR Standing Committee for International Clinical Studies 
Including Therapeutics. Ann Rheum Dis. 2008; 67(2): 195-205.. 
9.   Moroni G, Ponticelli C. Pregnancy after lupus nephritis. Lupus 
2005; 14: 89–94. 
10.  Doria A, Tincani A, Lockshin MD. Challenges of lupus preg-
nancies. Rheumatology 2008; 47: 9–12 
11.  Hochberg MC. Updating the American College of Rheumatol-
ogy revised criteria for the classification of systemic lupus ery-
thematosus. Arthritis Rheum 1997; 40: 1725. 
12.  Bombardier  C,  Gladman  DD,  Urowitz  MB,  Caron  D,  Chang 
CH. Derivation of the SLEDAI. A disease activity index for lu-
pus patients. The committee on prognosis studies in SLE. Ar-
thritis Rheum 1992; 35: 630–640 
13.  Hughes EC. Obstetric-gynaecologic terminology. Philadelphia: 
FA Davis. 1972: 423–442 
14.  Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic 
VD. A systematic review and meta-analysis of pregnancy out-
comes in patients with systemic lupus erythematosus and lupus 
nephritis. Clin J Am Soc Nephrol 2010; 5(11): 2060 –2068 
15.  Huong  DL,  Wechsler  B,  Vauthier-Brouzes  D,  Beaufils  H, 
Lefebvre G, Piette JC. Pregnancy in past or present lupus ne-
phritis: a study of 32 pregnancies from a single center. Ann 
Rheum Dis 2001; 60: 599–604. 
16.  Johns KR, Morand EF, Littlejohn GO. Pregnancy outcome in 
systemic lupus erythematosus. (SLE): a review of 54 cases. Aust 
N Z J Med 1998; 28: 18–22. 
17.  Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of 
pregnancy  on  lupus  nephritis.  Arthritis  Rheum  2004;  50: 
3941–3946. 
18.  Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo 
F, Vilardell-Tarres M. Clinical predictors of fetal and maternal 
outcome in systemic lupus erythematosus: a prospective study 
of 103 pregnancies. Rheumatology (Oxford) 2002; 41: 643–650. 
19.  Di Simone N, Raschi E, Testoni C, Castellani R, D'Asta M, Shi T, 
et al. Pathogenic role of anti-ß2-glycoprotein I antibodies in an-
tiphospholipid  associated  fetal  loss:  characterisation  of  ß 
2-glycoprotein I binding to trophoblast cells and functional ef-
fects of anti- ß 2-glycoprotein I antibodies in vitro. Ann Rheum 
Dis 2005; 64: 462–467. 
20.  Tincani A, Faden D, Biasini-Rebaioli C, et al. Pregnancy in SLE 
(2):  is  it  possible  to  predict  gestational  outcome?  Athritis 
Rheum 2002;812: 322 
21.  Mintz G, Nitz J, Gutierrez G, Karchmer S. Prospective study of 
pregnancy in systemic lupus erythematosus: results of a mul-
ti-disciplinary approach. J Rheumatol 1986; 13: 732–739.  